Clinical trial · Interventional
A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
A Phase I/II Study of OJP-001 for Recurrent or Relapsed Adult T-cell Leukemia/Lymphoma Patients With Peripheral Blood Tumor.
NCT07075328CI-TRIAL-00109706recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the tolerability of OJP-001, a therapeutic system combining photodynamic therapy (PDT) using OMD-001 and extracorporeal circulation therapy using OJE-001 and OJC-001, in patients with adult T-cell leukemia/lymphoma (ATL). The study will also investigate the recommended dose and pharmacokinetics of OMD-001, as well as the efficacy and safety of OJP-001.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma (ATLL) | Adult T-Cell Leukemia/Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Drug:5-ALA, Device:Photodynamic system | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- OJP-001 Group
- description
- Patients will receive 5-ALA administered orally once. After administration of 5-ALA, patients will receive OJP-001 once.
- interventionNames
- Other: Drug:5-ALA, Device:Photodynamic system
Primary outcomes (2)
- measure
- Phase I part: Dose limiting toxicity
- timeFrame
- Phase I part: 2 weeks
- measure
- Phase II part: Response rate (best overall response)
- timeFrame
- Phase II part: 24 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Hematocytologically or pathohistologically proven adult T-cell leukemia/lymphoma with positivity of anti-HTLV-1 antibody (Aggressive subtypes: acute, lymphoma type, or chronic type with unfavorable factor) * Age: 20-85 * Meeting the any following criteria for screening * Relapsed or recurrent ATL have history of treatment with mogamulizumab * At least one regimen of chemotherapy in case of intolerance/contraindication for mogamulizumab * Relapsed or recurrent ATL judged inadequate of treatment with mogamulizumab by investigators * Relapsed or recurrent ATL after allogeneic hematopoietic stem cell transplantation * Having peripheral blood lesion * ECOG performance status: 0-2 * T-Bil: =\< ULNx2, AST and ALT: =\< ULNx2.5 * Expected more than 3 months of survival Exclusion Criteria: * Body Weight \< 35kg * Hemoglobin \< 10g/dL * Splenomegaly * Subjects who received an following therapy * Chemotherapy or molecular-targeted agent for ATL : within 28 days prior to registration * Radiotherapy : within 28 days prior to registration * Any investigational drugs or medical devices (unapproved in Japan) : within 28 days prior to registration * Autologous stem cell transplantation : within 84 days prior to registration * Allogenic stem cell transplantation : within 100 days prior to registration * Administrated 5-ALA drug except study drug within 7 days prior to registration * Ate the foods containing 5-ALA or St. John's wort within 7 days prior to registration * Synchronous or metachronous malignancy * Uncontrolled severe complications * Porphyria * Uncontrolled cardiac arrhythmia or Chronic congestive heart failure (NYHA Class III or IV) * Uncontrolled inter-current illness including: heart failure, kidney failure, liver failure, hypertension, diabetes mellitus * Psychological disorder (mental illness, dementia, depression) * HBs-Ag positive or HBc-Ab positive with HBV-DNA positive * HCV-Ab positive * HIV-Ab positive * CNS involvement at screening * QTcF \> 470ms at screening * Uncontrolled intercurrent infection * Pregnant or nursing women * During participated in other clinical trials * Other inadequate conditions determined by investigators * In phase II part: subjects who registrated in phase I part of this trial
References
Publications (0)
Data not yet available
No reference posted for this study.